Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853189)
Watch
English
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
26181029
retrieved
13 November 2016
title
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma
(English)
1 reference
stated in
PubMed
PubMed ID
26181029
retrieved
13 November 2016
main subject
head and neck squamous cell carcinoma
0 references
author
Carrie Sougnez
series ordinal
15
0 references
Gad Getz
series ordinal
24
0 references
Nicolas Stransky
series ordinal
9
0 references
Aaron McKenna
series ordinal
21
0 references
Paul Johnston
object named as
Paul A Johnston
series ordinal
20
0 references
Simion Chiosea
object named as
Simion Chiosea
series ordinal
14
0 references
Jennifer Rubin Grandis
series ordinal
27
object named as
Jennifer R Grandis
0 references
Levi A Garraway
series ordinal
26
object named as
Levi A Garraway
0 references
Todd Golub
series ordinal
23
object named as
Todd R Golub
0 references
Jonas T. Johnson
series ordinal
6
object named as
Jonas T Johnson
0 references
David M Close
series ordinal
19
object named as
David Close
0 references
Gordon B. Mills
series ordinal
25
object named as
Gordon B Mills
0 references
author name string
Eliezer M Van Allen
series ordinal
1
0 references
Vivian W Y Lui
series ordinal
2
0 references
Ann Marie Egloff
series ordinal
3
0 references
Eva M Goetz
series ordinal
4
0 references
Hua Li
series ordinal
5
0 references
Umamaheswar Duvvuri
series ordinal
7
0 references
Julie E Bauman
series ordinal
8
0 references
Yan Zeng
series ordinal
10
0 references
Breean R Gilbert
series ordinal
11
0 references
Kelsey P Pendleton
series ordinal
12
0 references
Lin Wang
series ordinal
13
0 references
Nikhil Wagle
series ordinal
16
0 references
Fan Zhang
series ordinal
17
0 references
Yu Du
series ordinal
18
0 references
Scott L Carter
series ordinal
22
0 references
language of work or name
English
0 references
publication date
May 2015
0 references
published in
JAMA Oncology
1 reference
stated in
PubMed
volume
1
0 references
page(s)
238-44
0 references
issue
2
0 references
cites work
Response and acquired resistance to everolimus in anaplastic thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Genome sequencing identifies a basis for everolimus sensitivity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
Comprehensive genomic characterization of head and neck squamous cell carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
20 March 2017
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
7 April 2017
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
7 April 2017
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
7 April 2017
The mutational landscape of head and neck squamous cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
7 April 2017
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Landscape of genomic alterations in cervical carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
The UCSC Genome Browser database: extensions and updates 2011.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
29 September 2017
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
2 June 2018
Fine particulate matter induces amphiregulin secretion by bronchial epithelial cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4557203
retrieved
27 November 2018
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26181029
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26181029
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1001/JAMAONCOL.2015.34
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5033266
OpenCitations bibliographic resource ID
5033266
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5033266
PMCID
4557203
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5033266
PubMed ID
26181029
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
5033266
ResearchGate publication ID
276835782
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
